Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study

Abstract Background We aim to investigate comparative dementia risk associated with glucagon-like peptide-1 receptor agonists (GLP1-RAs), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and dipeptidyl peptidase-4 inhibitors (DPP4i) in adults aged ≥ 60 years with type 2 diabetes. Methods This tar...

Descripció completa

Dades bibliogràfiques

Autors principals:	Che-Yuan Wu, Wajd Alkabbani, Baiju R. Shah, Moira K. Kapral, Jodi D. Edwards, Colleen J. Maxwell, Walter Swardfager
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-12-01
Col·lecció:	Alzheimer’s Research & Therapy
Matèries:	Sodium Glucose cotransporter 2 (SGLT2) inhibitor, Glucagon Like peptide 1 (GLP1) receptor agonist, Dipeptidyl peptidase 4 (DPP4) inhibitors, Diabetes, Dementia
Accés en línia:	https://doi.org/10.1186/s13195-025-01929-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!